Referanser

1. Cancer in Norway 2008, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
2. de Vires E & Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355–66
3. de Vires E , Bray F, Coebergh JW in DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1967–1997: rising trends in incidence and mortality, but stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119–26
4. Marghoob AA. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arc Dermatol 1996; 132: 170–5
5. Rockley PF. Non risk factors for malignant melanoma. Chemical agents, physical conditions and occupation. Int J Dermatol 1994; 33: 398–405
6. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trail. JAMA 1998; 280: 1485–9
7. Huber MR, Markovic SN. Adjuvant nodal radiotherapy for node positive head and neck melanoma: A single institution experience. Proc Am Soc Clin Oncol 2004; 23: 716, abstract 7537
8. Kraehn GM, Schartl M, Peter RU. Human malignant melanoma. A genetic disease? Cancer 1995; 75: 1228–37
9. Balch CM, Houghton AN, Milton GW et al. red. Cutaneous melanoma. 2. utg. Philadelphia: Lippincott, 1992: 165–86
10. Massback A, Olsson H, Westerdahl J et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11: 435–45
11. Seregard S. Posterior uvealt melanoma. The Swedish perspective. Acta Ophthalmol Scand 1996; 74: 315–329
12. Veileder 2007. Norsk Melanomgruppe
13. TNM Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 5th Edition 2004.